help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

The Oncologist, Vol. 11, No. 4, 358-373, April 2006; doi:10.1634/theoncologist.11-4-358
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ettinger, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ettinger, D. S.

Lung Cancer

Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Non-Small Cell Lung Cancer

David S. Ettinger

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Key Words. EGFR • Cancer therapy • Lung cancer • Anti-EGFR agents

Correspondence: David S. Ettinger, M.D., The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Bunting Blaustein Cancer Research Bldg., 1650 Orleans Street, Room G88, Baltimore, Maryland 21213-1000, USA. Telephone: 410-955-8847; Fax: 410-614-9424; e-mail: ettinda{at}jhmi.edu

Dysregulation of the epidermal growth factor receptor (EGFR) signaling pathway is associated with the development and progression of malignancy, and EGFR-targeted therapies offer the promise of better treatment for many types of solid tumors, including non-small cell lung cancer. Anti-EGFR agents include monoclonal antibodies (mAbs) targeting the EGFR extracellular receptor domain and small-molecule tyrosine kinase inhibitors (TKIs) targeting the EGFR intracellular kinase domain. Both mAbs and TKIs have demonstrated encouraging results as monotherapies and in combination with chemotherapy and radiotherapy. This review provides a critical update on the status of these novel therapeutics.




This article has been cited by other articles:


Home page
 JNMHome page
N. Liu, M. Li, X. Li, X. Meng, G. Yang, S. Zhao, Y. Yang, L. Ma, Z. Fu, and J. Yu
PET-Based Biodistribution and Radiation Dosimetry of Epidermal Growth Factor Receptor-Selective Tracer 11C-PD153035 in Humans
J. Nucl. Med., February 1, 2009; 50(2): 303 - 308.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Kumar, K. G. Cordell, J. S. Lee, F. P. Worden, M. E. Prince, H. H. Tran, G. T. Wolf, S. G. Urba, D. B. Chepeha, T. N. Teknos, et al.
EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer
J. Clin. Oncol., July 1, 2008; 26(19): 3128 - 3137.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H.-P. Kim, S.-W. Han, S.-H. Kim, S.-A. Im, D.-Y. Oh, Y.-J. Bang, and T.-Y. Kim
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells
Mol. Cancer Ther., March 1, 2008; 7(3): 607 - 615.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor
Clin. Cancer Res., March 1, 2007; 13(5): 1540 - 1551.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.